Abstract 5219
Background
Optimising quality of life (QoL) remains the central tenet of care in patients with incurable cancer, however determinants of this are not clear.
Methods
Multi-centre study conducted across 18 sites in Ireland and United Kingdom over a period of 5 years (2011-2016). Data collected included: patient demographics, Performance Status (ECOG-PS), weight loss (%WL) and skeletal muscle index (SMI) and skeletal muscle attenuation (MA) assessed by CT images, inflammatory markers [modified Glasgow Prognostic score (mGPS)] and QoL data (EORTC QLQ-30). The relationship between clinical and nutritional parameters with QoL was assessed using the Spearman rank correlation coefficient & multivariate binary logistic regression.
Results
Data were available on 1027 patients, of which 51% were male and the median age was 66 (IQR 57-74) years. Gastrointestinal cancer was most prevalent (40%) and 87% of patients had metastatic disease. %WL, ECOG-PS and mGPS were significantly correlated with deteriorating QoL functional & symptom scales (all p < 0.001). On multivariate regression analysis, >10% WL (OR 2.69 [95% CI: 1.63-4.42]), ECOG-PS 3-4 (OR 14.33 [95% CI: 6.76- 30.37]) and mGPS score 2 (OR 1.58 [95% CI: 1.09- 2.29]) were independently associated with poorer summary QoL score. WL & mGPS were also independently associated with poor physical function, fatigue and appetite loss (all p < 0.05). Low MA was independently associated with poor physical function (OR 1.67 [95% CI: 1.09-2.56]), but not with fatigue, appetite or QoL summary score.
Conclusions
The findings indicate that QoL is determined in part by WL, ECOG-PS and systemic inflammation in patients with advanced cancer. Although muscle parameters were associated with some QoL domains, no significant independent association with fatigue, appetite loss or QoL summary score was observed. Identifying early predictors of poor QoL may allow the identification of patients who may benefit from early referral to palliative care, which has been shown to improve QoL.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4615 - Proteomic Profiling Identifies Molecular Basis of Adverse Event to BPM31510 Exposure: Rationale for Comprehensive Molecular Pharmacodynamics (PD) in Phase 1 Clinical Trial Design
Presenter: Vivek Subbiah
Session: Poster Display session 1
Resources:
Abstract
5052 - Identification of first-in-class, naturally occurring LAG3 checkpoint inhibitor
Presenter: Gennady Bratslavsky
Session: Poster Display session 1
Resources:
Abstract
5336 - Are Epigenetic therapies modifying sensitivity to conventional chemotherapy?
Presenter: Alexandra Bizot
Session: Poster Display session 1
Resources:
Abstract
5739 - Oncogenic mutations at the dimer interface of EGFR lead to formation of covalent homo-dimers and allosteric activation of the kinase domain: A mechanism which alters the selectivity profile of oncogenic EGFR.
Presenter: Elizabeth Buck
Session: Poster Display session 1
Resources:
Abstract
5492 - Basic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer
Presenter: Rui Xiong
Session: Poster Display session 1
Resources:
Abstract
5965 - EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
Presenter: Ronan Le Moigne
Session: Poster Display session 1
Resources:
Abstract
3582 - AVID200 neutralizes TGF-beta1 and -beta3, the principal immunosuppressive TGF-beta isoforms overexpressed by tumors, and sensitizes tumors to immune checkpoint inhibitors.
Presenter: Tina Gruosso
Session: Poster Display session 1
Resources:
Abstract
1996 - High NAMPT expression and anti-tumor activity of NAMPT inhibitor in adult T-cell leukemia/lymphoma
Presenter: Tomohiro Kozako
Session: Poster Display session 1
Resources:
Abstract
4307 - TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers
Presenter: Alexander Drilon
Session: Poster Display session 1
Resources:
Abstract
4869 - In Vivo Evaluation of Cisplatin-loaded PEG-PCL Block Copolymeric Nanoparticles for Anticancer Drug Delivery
Presenter: Yingtzu Yen
Session: Poster Display session 1
Resources:
Abstract